Molecular theranostic based on esterase-mediated drug activation for hepatocellular carcinoma
Source abstract
Abstract
Abstract In past few years, cancer specific targeted drug formulations have shown some hope of improving the therapeutics with minimized associated side effects of chemotherapy. However, the benefits has proven modest due to lack of systems that can be assessed easily from parent drugs while maintaining the same features of cancer associated prodrug activation. We developed a small molecule-based, carboxylesterase responsive theranostic, EDOX, with tumor-specific enzymatic activation for targeted delivery of the anticancer drug, Doxorubicin (Dox), to hepatocellular carcinoma (HCC) cells. Easy synthetic access, physiological stability, tumor-selective activation, and sustained drug release make EDOX an excellent candidate for use as a next-generation drug delivery system for HCC.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Hallmarks of cancer: the next generation10.1016/j.cell.2011.02.013 ↗
2. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States10.1158/0008-5472.CAN-14-0155 ↗
3. A history of exploring cancer in context10.1038/s41568-018-0006-7 ↗
4. Novel concept of the smart NIR-light-controlled drug release of black phosphorus nanostructure for cancer therapy10.1073/pnas.1714421115 ↗
5. Black phosphorus analogue tin sulfide nanosheets: synthesis and application as near-infrared photothermal agents and drug delivery platforms for cancer therapy10.1039/C8TB00729B ↗
6. Ultrasmall black phosphorus quantum dots: synthesis and use as photothermal agents10.1002/anie.201506154 ↗
7. Omnipotent phosphorene: a next-generation, two-dimensional nanoplatform for multidisciplinary biomedical applications10.1039/C8CS00342D ↗
8. Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint Adaptation in proliferating cancer cells10.3390/ijms15033403 ↗
9. Review: side effects of approved molecular targeted therapies in solid cancers10.1634/theoncologist.12-12-1443 ↗
10. Global cancer statistics, 201210.3322/caac.21262 ↗
11. Hepatocellular carcinoma10.1038/nrdp.2016.18 ↗
12. Elucidation of the mechanism enabling tumor selective prodrug monotherapy
13. Chemotherapy for advanced hepatocellular carcinoma10.1111/j.1440-1746.2008.05444.x ↗
14. Interleukin-6 alters the cellular responsiveness to clopidogrel, irinotecan, and Oseltamivir by suppressing the expression of Carboxylesterases HCE1 and HCE210.1124/mol.107.036889 ↗
15. Characterization of recombinant human carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 210.1124/dmd.111.039628 ↗
16. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma10.1002/pmic.200900105 ↗
17. Deficiency of carboxylesterase 1/esterase-x results in obesity, hepatic steatosis, and hyperlipidemia10.1002/hep.25961 ↗
18. Enzyme-instructed assembly and disassembly processes for targeting downregulation in cancer cells10.1021/jacs.7b00070 ↗
19. A highly selective ratiometric fluorescent probe for in vitro monitoring and cellular imaging of human carboxylesterase 110.1016/j.bios.2014.01.049 ↗
20. Design, synthesis, and preliminary evaluation of doxazolidine carbamates as prodrugs activated by carboxylesterases10.1021/jm060597e ↗
21. Fluorogenic reaction-based prodrug conjugates as targeted cancer theranostics10.1039/C7CS00557A ↗
22. Nanotechnology for multimodal synergistic cancer therapy10.1021/acs.chemrev.7b00258 ↗
23. Organic molecule-based photothermal agents: an expanding photothermal therapy universe10.1039/C7CS00522A ↗
24. Nanochemistry and nanomedicine for nanoparticle-based diagnostics and therapy10.1021/acs.chemrev.5b00148 ↗
25. Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation10.1016/j.biomaterials.2017.11.019 ↗
26. Overcoming drug resistance by targeting cancer bioenergetics with an activatable prodrug10.1016/j.chempr.2018.08.002 ↗
27. Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy10.1016/j.jconrel.2018.08.036 ↗
28. COX-2 Inhibition mediated anti-angiogenic activatable prodrug potentiates cancer therapy in preclinical models10.1016/j.biomaterials.2018.09.006 ↗
29. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
30. Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions10.1021/acsnano.6b08244 ↗
31. A survey of Hammett substituent constants and resonance and field parameters10.1021/cr00002a004 ↗
32. Identification of tissue-restricted bioreaction suitable for in vivo targeting by fluorescent substrate library-based enzyme discovery10.1021/jacs.5b05884 ↗
33. A two-photon ratiometric fluorescent probe for imaging carboxylesterase 2 in living cells and tissues10.1021/acsami.5b09573 ↗
34. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy10.1021/jm0101996 ↗
35. Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease10.1039/C6CC04255D ↗
36. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo10.1073/pnas.0601755103 ↗
37. Human carboxylesterases: an update on CES1, CES2 and CES310.2174/092986609789071324 ↗
38. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells10.1158/1078-0432.CCR-12-1184 ↗
39. Quantitative proteomics analysis of the hepatitis C virus replicon high-permissive and low-permissive cell lines10.1371/journal.pone.0142082 ↗
40. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma10.1186/s13046-018-0772-9 ↗
41. TRIB3 downregulation enhances doxorubicin-induced cytotoxicity in gastric cancer cells10.1016/j.abb.2017.04.008 ↗
42. PARP1 regulates the protein stability and proapoptotic function of HIPK210.1038/cddis.2016.345 ↗
43. Dissecting the mechanisms of doxorubicin and oxidative stress-induced cytotoxicity: the involvement of actin cytoskeleton and ROCK110.1371/journal.pone.0131763 ↗
44. Utility of the carboxylesterase inhibitor bis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor10.3109/00498251003706598 ↗